The coronavirus SARS-CoV-2 is the cause of the ongoing COVID-19 pandemic. Therapeutic
neutralizing antibodies constitute a key short-to-medium term approach to tackle COVID-19 …

Since the start of the COVID-19 pandemic, multiple waves of SARS-CoV-2 variants have
emerged. Of particular concern is the omicron variant, which harbors 28 mutations in the …

The SARS-CoV-2 virus is more transmissible than previous coronaviruses and causes a
more serious illness than influenza. The SARS-CoV-2 receptor binding domain (RBD) of the …

Antibody therapeutics for the treatment of COVID-19 have been highly successful. However,
the recent emergence of the Omicron variant has posed a challenge, as it evades detection …

Abstract Monoclonal anti‐SARS‐CoV‐2 immunoglobulins represent a treatment option for
COVID‐19. However, their production in mammalian cells is not scalable to meet the global …

Neutralizing antibodies represent a valuable therapeutic approach to countermeasure the
current COVID-19 pandemic. Emergence of SARS-CoV-2 variants emphasizes the notion …

Abstract SARS-CoV-2, the causative agent of COVID-19, features a receptor-binding domain
(RBD) for binding to the host cell ACE2 protein,,,,–. Neutralizing antibodies that block RBD …

Because of the evolutionary variants of SARS-CoV-2, development of broad-spectrum
neutralizing antibodies resilient to virus escape is urgently needed. We identified a group of …

The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants
threatens efforts to contain the coronavirus disease 2019 (COVID-19) pandemic. Omicron …

COVID-19 pandemic caused by SARS-CoV-2 constitutes a global public health crisis with
enormous economic consequences. Monoclonal antibodies against SARS-CoV-2 can …